HeartSciences Inc. Files 8-K Report

TL;DR

HeartSciences Inc. filed an 8-K on 8/22/25 with updated office info.

AI Summary

On August 22, 2025, HeartSciences Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 550 Reserve Street, Suite 360, Southlake, Texas, 76092. The company's telephone number is 682-237-7781. This report is filed under the 'Other Events' section.

Why It Matters

This 8-K filing provides updated contact and location information for HeartSciences Inc., which is important for investors and stakeholders to have the most current details.

Risk Assessment

Risk Level: low — The filing is a routine update of corporate information and does not contain any material financial or operational disclosures that would indicate significant risk.

Key Players & Entities

• HeartSciences Inc. (company) — Registrant
• 550 Reserve Street, Suite 360, Southlake, Texas, 76092 (location) — Principal Executive Offices
• 682-237-7781 (phone_number) — Registrant's Telephone Number
• August 22, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $3.50 — y (the "Units") at an offering price of $3.50 per Unit, for a maximum offering amount
• $15,000,000 — Unit, for a maximum offering amount of $15,000,000 worth of Units (collectively, the "Offe
• $0.001 — y's Series D Preferred Stock, par value $0.001 per share (the "Series D Preferred Stoc
• $5.00 — common stock"), at an exercise price of $5.00 per share. As of August 22, 2025, the
• $5.2 million — 25, the Company has received a total of $5.2 million of gross proceeds, resulting in the iss
• $1,655,000 — ust 22, 2025, the Company has exchanged $1,655,000 of an unsecured promissory note issued

Filing Documents

• hscs-20250822.htm (8-K) — 51KB
• 0001468492-25-000003.txt ( ) — 188KB
• hscs-20250822.xsd (EX-101.SCH) — 45KB
• hscs-20250822_htm.xml (XML) — 6KB

01 Other Events

Item 8.01 Other Events. Regulation A Offering As previously disclosed, on February 12, 2025, HeartSciences, Inc. (the "Company") filed an Offering Statement on Form 1-A (File No. 024-12572) (as amended and supplemented from time to time, the "Form 1-A"), with the U.S. Securities and Exchange Commission (the "SEC") and which was qualified by the SEC on March 10, 2025, to register the offering of up to 4,285,714 units of the Company (the "Units") at an offering price of $3.50 per Unit, for a maximum offering amount of $15,000,000 worth of Units (collectively, the "Offering"). Each Unit consists of one share of the Company's Series D Preferred Stock, par value $0.001 per share (the "Series D Preferred Stock") and one warrant (each a "Warrant" and collectively the "Warrants") to purchase one share of the Company's common stock, $0.001 par value per share (the "common stock"), at an exercise price of $5.00 per share. As of August 22, 2025, the Company has received a total of $5.2 million of gross proceeds, resulting in the issuance of 1,484,440 Units, as a result of several closings of the Offering. As of August 22, 2025, holders of 979,851 shares of Series D Preferred Stock, received as part of the issued Units, have elected to convert such shares of Series D Preferred Stock into 979,851 shares of common stock (the "Reg A Issuance"). Debt Exchange As of August 22, 2025, the Company has exchanged $1,655,000 of an unsecured promissory note issued to a certain third party in September 2024 for 461,572 shares of the Company's common stock, reducing the principal amount of such note by such amount (the "Debt Exchange"). As a result of the Reg A Issuance and the Debt Exchange, there are 2,535,066 shares of common stock issued and outstanding as of August 22, 2025.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 104* Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEARTSCIENCES INC. Date: August 22, 2025 By: /s/ Andrew Simpson Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR